JenaValve

JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients with heart valve disease. The company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement ("TAVR") system designed to treat high-surgical-risk patients with symptomatic severe aortic regurgitation ("AR") and aortic stenosis ("AS"). The Trilogy system received CE Mark approval in May 2021, providing European physicians with the first truly dual-pathology treatment device.